27210-70-4

Basic information

• Product Name: AKOS B007547
• Synonyms: 2-aminobenzene-1,4-dicarboxylic acid diethyl ester;diethyl 2-aminobenzene-1,4-dicarboxylate;IVK/1004424;Oprea1_481642;ART-CHEM-BB B007547;AKOS B007547;Diethyl 2-aminoterephthalate;2-Amino-1,4-benzenedicarboxylic acid 1,4-diethyl ester
• CAS NO: 27210-70-4
• Molecular Formula: C₁₂H₁₅NO₄
• Molecular Weight: 237.25
• Mol File: 27210-70-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 56-57 °C
• Boiling Point: 370.5°C at 760 mmHg
• Flash Point: 167.4°C
• Appearance: /
• Density: 1.183g/cm³
• Vapor Pressure: 1.1E-05mmHg at 25°C
• Refractive Index: 1.544
• PKA: 1.32±0.10(Predicted)
• CAS DataBase Reference: AKOS B007547(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS B007547(27210-70-4)
• EPA Substance Registry System: AKOS B007547(27210-70-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 27210-70-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H15NO4/c1-3-16-11(14)8-5-6-9(10(13)7-8)12(15)17-4-2/h5-7H,3-4,13H2,1-2H3

Upstream product

• 610-29-7 2-nitroterephthalic acid 
• 39020-35-4 2-nitroterephthalic acid diethyl ester 

Downstream Products

• 86373-92-4 2-[3-(4-Chloro-phenyl)-propylamino]-terephthalic acid 
• 479065-45-7 2,5-bis(methoxyacetamido)-1,4-bis(n-propylcarbamyl)benzene 
• 479065-40-2 2,5-bis(methoxyacetamido)terephthalic acid diethyl ester 
• 479065-38-8 2-(methoxyacetamido)-5-nitroterephthalic acid diethyl ester 
• 479065-39-9 2-(methoxyacetamido)-5-aminoterephthalic acid diethyl ester 
• 479065-37-7 2-(methoxyacetamido)terephthalic acid diethyl ester 

Relevant articles and documents

BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as "BPSAAA compounds"), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment and/or prevention, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer associated bone disease, Paget's disease and the like.